Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the single-dose relative bioavailability of
Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following
an oral, single 20 mg (2 x 10 mg) dose under fasting conditions.